학술논문
ARX788, a site-specific anti-HER2 antibody–drug conjugate, demonstrates potent and selective activity in HER2-low and T-DM1–resistant breast and gastric cancers
Document Type
Article
Author
Source
In: Molecular Cancer Therapeutics . (Molecular Cancer Therapeutics, 1 September 2020, 19(9):1833-1843)
Subject
Language
English
ISSN
15388514
15357163
15357163